Peginterferon Alfa-2A
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Peginterferon Alfa-2A |
| DrugBank ID | DB00008 |
| Brand Names (EU) | Pegasys |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.99% |
Approved Indication (EMA)
Polycythaemia veraPegasys is indicated as monotherapy in adults for the treatment of polycythaemia vera. Essential thrombocythaemiaPegasys is indicated as monotherapy in adults for the treatment of essential thrombocythaemia..Chronic hepatitis BAdult patientsPegasys is indicated for the treatment of hepatitis B envelope antigen (HBeAg)-positive or HBeAg-negative chronic hepatitis B (CHB) in adult patients with compensated liver disease and evidence of viral replication, increased alanine am
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | chronic hepatitis C virus infection | 99.99% | DL |
| 2 | hepatitis B virus infection | 99.94% | DL |
| 3 | hepatitis C virus infection | 99.91% | DL |
| 4 | hepatitis E virus infection | 99.83% | DL |
| 5 | hepatitis A virus infection | 99.82% | DL |
| 6 | hepatitis, viral, animal | 99.82% | DL |
| 7 | Omsk hemorrhagic fever | 99.82% | DL |
| 8 | chronic hepatitis B virus infection | 99.81% | DL |
| 9 | Kyasanur forest disease | 99.81% | DL |
| 10 | heart conduction disease | 99.50% | DL |
| 11 | heart neoplasm | 99.37% | DL |
| 12 | heart valve disease | 99.36% | DL |
| 13 | congenital anomaly of ventricular septum | 99.23% | DL |
| 14 | pericardium disease | 99.13% | DL |
| 15 | myocardial rupture | 99.03% | DL |
| 16 | cor biloculare | 99.03% | DL |
| 17 | carcinoid heart disease | 99.03% | DL |
| 18 | cardiac anomalies-heterotaxy syndrome | 99.03% | DL |
| 19 | heart aneurysm | 99.03% | DL |
| 20 | white forelock with malformations | 98.68% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.